ORGANOPlus

ORGANOPlus is an R&D‑driven biotech company developing a fully animal‑free, human‑relevant intestinal organoid‑chip platform for preclinical testing. Patient‑derived villus‑specific organoids are integrated into microfluidic chips to recreate native gut physiology and host–microbe interactions, enabling end‑to‑end assessment of live‑biotherapeutic products (LBPs), probiotics and small‑molecule drug candidates under conditions that more accurately predict human responses than conventional in vitro or animal models.

Core services delivered today
•  Quantitative bacterial adhesion & colonisation assays
•  Inflammation modelling and mechanism‑of‑action (MoA) analysis
•  High‑throughput drug screening on intestinal, tumour or multi‑organ chips

Pipeline & future capabilities
•  AI‑enhanced PBPK analytics are under active development; validation studies are scheduled to integrate chip‑derived pharmacokinetic data into predictive, regulator‑accepted in‑silico models.

Partner value
•  CROs that retrofit their existing screening workflows with OrganoPlus organoid‑chips gain higher human relevance without building new wet‑labs—making them priority target customers and co‑development partners.
•  Pharma, biotech and functional‑food companies receive NAM‑compliant data packages that accelerate decision‑making while supporting global animal‑reduction mandates (FDA, EMA).

Operating as a service‐oriented technology provider, OrganoPlus offers custom chip fabrication, data analytics (SaaS) and strategic collaborations to help partners cut R&D costs, de‑risk pipelines and bring microbiome therapeutics and novel drugs to patients faster and more ethically.